← Browse by Condition
Medical Condition

aggressive non hodgkin lymphoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT05260957 Phase 2
Recruiting

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Enrollment
22 pts
Location
United States
Sponsor
Lazaros Lekakis
View Trial →